id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2007-D-0433-0009,FDA,FDA-2007-D-0433,Draft Guidances for Industry; Bioequivalence Recommendation for Lenalidomide Capsules,Other,Guidance,2012-11-06T05:00:00Z,2012,11,2012-11-06T05:00:00Z,,2024-11-11T20:43:53Z,,1,0,090000648115f67b
FDA-2007-D-0433-0008,FDA,FDA-2007-D-0433,Draft Guidances for Industry; Availability: Bioequivalence Recommendation for Lenalidomide Capsules,Notice,Notice of Availability,2012-11-06T05:00:00Z,2012,11,2012-11-06T05:00:00Z,2013-01-08T04:59:59Z,2013-01-08T03:27:42Z,2012-27004,0,0,090000648115f3c3
FDA-2007-D-0433-0004,FDA,FDA-2007-D-0433,Guidance for Industry on Bioequivalence Recommendations for Specific Products; Availability,Notice,N-Notice,2010-06-11T04:00:00Z,2010,6,2010-06-11T04:00:00Z,,2010-10-29T01:09:58Z,2010-14036,0,0,0900006480b002bd
FDA-2007-D-0433-0005,FDA,FDA-2007-D-0433,Guidance for Industry: Bieoquivalence Recommendations for Specific Products,Other,Guidance,2010-06-10T04:00:00Z,2010,6,2010-06-10T04:00:00Z,,2024-11-07T22:22:18Z,,1,0,0900006480b0054a
FDA-2007-D-0433-0002,FDA,FDA-2007-D-0433,Guidance,Supporting & Related Material,GDL-Guidance,2007-06-13T04:00:00Z,2007,6,,,2008-04-04T00:34:43Z,,0,0,090000648042dc7b
FDA-2007-D-0433-0003,FDA,FDA-2007-D-0433,Guidance,Supporting & Related Material,GDL-Guidance,2007-06-13T04:00:00Z,2007,6,,,2008-04-04T00:34:43Z,,0,0,090000648042dc7c
FDA-2007-D-0433-0001,FDA,FDA-2007-D-0433,FDA,Notice,NAD-Notice of Availability of Data,2007-06-06T04:00:00Z,2007,6,2007-05-30T04:00:00Z,2007-08-30T03:59:59Z,2008-04-04T00:34:43Z,,0,0,090000648042dc7a